Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
Recruiting now · Not applicable
Conditions studied: Chronic Limb-Threatening Ischemia
In brief
The objective of this prospective, single-blinded, randomized controlled trial is to evaluate the safety and efficacy of the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Approximately 276 subjects will be randomized in a 1:1 ratio. The clinical investigation will be conducted at up to 60 clinical sites globally.
Key facts
- Study ID
- NCT06071429
- Run by
- R3 Vascular Inc.
- People needed
- 300
- Starts
- 2025-04-11
- Expected to finish
- 2032-03-01
- Last updated by the study team
- 2026-02-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- NYU Langone Health — New York, New York, United States (enrolling)
- CUMC/NYP — New York, New York, United States (enrolling)
- Staten Island University Hospital - Northwell Health — Staten Island, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.